Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L. Locke, Jason R. Westin, Marie José Kersten et al.|New England Journal of Medicine|2021Cited by 1.6k
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R. Westin, Anna Sureda, Frederick L. Locke et al.|Clinical Cancer Research|2023Cited by 51